Versor Investments LP Purchases Shares of 20,200 Sotera Health (NASDAQ:SHC)

Versor Investments LP acquired a new position in Sotera Health (NASDAQ:SHC) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 20,200 shares of the company’s stock, valued at approximately $337,000.

Other large investors have also recently made changes to their positions in the company. Janus Henderson Group PLC increased its position in shares of Sotera Health by 43.6% during the first quarter. Janus Henderson Group PLC now owns 14,892,868 shares of the company’s stock valued at $178,865,000 after buying an additional 4,525,056 shares during the period. Vanguard Group Inc. raised its position in shares of Sotera Health by 27.0% in the 1st quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock worth $145,863,000 after acquiring an additional 2,579,248 shares in the last quarter. Sessa Capital IM L.P. lifted its stake in shares of Sotera Health by 7.5% in the 2nd quarter. Sessa Capital IM L.P. now owns 4,300,597 shares of the company’s stock valued at $51,048,000 after purchasing an additional 300,597 shares during the period. Darsana Capital Partners LP bought a new stake in shares of Sotera Health during the second quarter valued at approximately $29,074,000. Finally, Untitled Investments LP boosted its position in shares of Sotera Health by 47.0% during the first quarter. Untitled Investments LP now owns 1,409,091 shares of the company’s stock valued at $16,923,000 after purchasing an additional 450,496 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Stock Performance

Shares of Sotera Health stock opened at $14.31 on Friday. The stock has a market cap of $4.05 billion, a price-to-earnings ratio of 58.00 and a beta of 2.08. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44. The firm’s 50-day moving average is $15.96 and its 200 day moving average is $13.85.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $285.47 million during the quarter, compared to the consensus estimate of $278.64 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The company’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.18 EPS. Sell-side analysts anticipate that Sotera Health will post 0.61 EPS for the current fiscal year.

Insider Buying and Selling at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the transaction, the director now owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. This represents a 16.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 55.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on SHC shares. Barclays raised their price objective on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Citigroup boosted their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.